Severe Outcomes of Respiratory Viral Infections in a US Healthcare System, 2022–2023

835,987 patients triple-tested for SARS-CoV-2, influenza, and RSV in the US Veterans Health Administration during 2022–2023. The dataset, authored by Janet M. Grubber, compares frequencies of hypoxemia and death across single and multiple infections using multivariable logistic regression. It was last updated on April 22, III.

Use Cases

• Modeling the adjusted odds of severe outcomes like hypoxemia based on infection status.
• Comparing mortality risk between SARS-CoV-2, influenza, and RSV infections.
• Studying the rarity and impact of multiple viral co-infections in a clinical population.
• Analyzing the effect of routine testing policies on outcome measurement without confounding by indication.

Strengths

• Includes data from 835,987 patients, providing a large sample size.
• Reports specific outcome frequencies, such as 8.0% hypoxemia with SARS-CoV-2 and 0.2% co-infection rate.
• Provides adjusted odds ratios with confidence intervals for hypoxemia and death across virus types.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data is limited to the US Veterans Health Administration population, which may not be generalizable.

Provenance

Source

figshare, authored by Janet M. Grubber.

Collection Method

Routine clinical testing records from the US Veterans Health Administration.

Time Range

2022–2023

Freshness

Last updated 2026-04-22 05:46:29; freshness should be verified.

Geography

United States (Veterans Health Administration system)